Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 10Lymphoid 3Thoracic 2Dermatologic 2Other solid neoplasm 1Other hematologic neoplasm 1Other 1Gynecologic 1Genitourinary 1

Conditions

Lymphoma 539Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Lymphoma, Non-Hodgkin 435Lymphoma, Follicular 403Leukemia, Lymphocytic, Chronic, B-Cell 388Lymphoma, Large B-Cell, Diffuse 385Lymphoma, B-Cell 246Lymphoma, Mantle-Cell 222Hodgkin Disease 207Recurrence 204Leukemia, Myeloid, Acute 197Leukemia 191Multiple Myeloma 184Burkitt Lymphoma 181Lymphoma, B-Cell, Marginal Zone 170Neoplasms 151Myelodysplastic Syndromes 132Hematologic Neoplasms 115Waldenstrom Macroglobulinemia 103Lymphoma, T-Cell, Peripheral 85Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 81Lymphoma, T-Cell 81Lymphoma, T-Cell, Cutaneous 66Leukemia, Myelogenous, Chronic, BCR-ABL Positive 62Mycosis Fungoides 57Leukemia, Biphenotypic, Acute 54Breast Neoplasms 54Myeloproliferative Disorders 50Leukemia, B-Cell 50Lymphoproliferative Disorders 47

Interventions

NX-13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Colitis, Ulcerative × Lymphoid × 1 year × Clear all
NCT02808780 2026-06-05

OPAL

Janssen Biotech, Inc.

Active not recruiting
535 enrolled
Lymphoid

Colitis, Ulcerative, Lymphoma, Neoplasms

NCT05156125 2026-04-30

VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Oppilan Pharma Ltd

Phase 2 Terminated
213 enrolled 19 charts
Lymphoid

Colitis, Ulcerative, Lymphoma, Follicular

NCT05785715 2025-07-01

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

AbbVie

Phase 2 Terminated
81 enrolled
Lymphoid

Colitis, Ulcerative, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡